Kopanakis Nikolaos, Efstathiou Elias, Sarris Dimitrios, Spiliotis John
Department of Surgical Oncology, Metaxa Cancer Hospital, Piraeus, Greece.
J BUON. 2017 Sep-Oct;22(5):1144-1147.
Gastric cancer (GC) remains the second leading cause of cancer death worldwide, accounting for 8% of the total cases and 10% of total deaths in 2008. Surgery remains the curative treatment option for GC and the main reason for treatment failure is peritoneal recurrence which, according to the literature, occurs in 40-60% of the cases, despite extensive surgery including D2 lymph node dissection. The hyperthermic intraperitoneal chemotherapy (HIPEC) technique is increasingly used in the treatment of primary and digestive peritoneal carcinomatosis (PC), in association with cytoreductive surgery (CRS). We retrospectively analyzed 14 patients with gastric peritoneal carcinomatosis (GPC) undergoing CRS/HIPEC in the last 10 years. Six patients already had GPC at the time of diagnosis (group A) and 8 developed metachronous GPC (group B). Treatment with CRS and HIPEC didn't seem to confer a survival benefit to patients with synchronous PC from gastric cancer.
胃癌（GC）仍是全球癌症死亡的第二大主要原因，2008年占总病例数的8%，总死亡数的10%。手术仍然是胃癌的治愈性治疗选择，治疗失败的主要原因是腹膜复发，据文献报道，尽管进行了包括D2淋巴结清扫在内的广泛手术，但仍有40-60%的病例会出现腹膜复发。热灌注化疗（HIPEC）技术越来越多地用于原发性和消化道腹膜癌病（PC）的治疗，并与细胞减灭术（CRS）联合使用。我们回顾性分析了过去10年中接受CRS/HIPEC治疗的14例胃腹膜癌病（GPC）患者。6例患者在诊断时已患有GPC（A组），8例发生异时性GPC（B组）。CRS和HIPEC治疗似乎并未给同步性胃癌PC患者带来生存益处。
